ISIS/Genzyme’s Kynamro involves a subcutaneous injection and is currently priced at $176,000 per patient per year. Kynamro, as a biologic, also requires cold storage. Coinciding with the company’s ...

In the KYNAMRO clinical trial in patients with HoFH, 4 (12%) of the 34 patients treated with KYNAMRO compared with 0% of the 17 patients treated with placebo had at least one elevation in alanine ...

Kynamro will be available in a 200mg/mL dosage strength as 1mL single-use vials and prefilled syringes. For more information call (877) 596-2676 or visit www.kynamro.com ...

KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C ...

For those with HoFH, heart attacks and death often occur before age 30. Kynamro is an orphan drug approval, meaning it was developed to treat a disorder affecting fewer than 200,000 people.

Kynamro is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce LDL-C, apolipoprotein B (apo B), total ...

Kynamro has poor long-term tolerability. Kynamro is highly immunogenic in humans. Kynamro adverse events are associated with immune response. Kynamro's long-term tolerability is likely to be ...

Kynamro is an important drug to Ionis, and most important to the patients who depend on it, Boyce said. The company’s first priority is to make sure those patients continue to get Kynamro.

We had, during the second $25 million milestone payment, associated with FDA approval of KYNAMRO this year and included this milestone payment in our 2012 guidance.

KYNAMRO contains a Boxed Warning citing the risk of hepatic toxicity. Patients taking KYNAMRO should have liver enzyme testing before starting the drug and periodically thereafter.

KYNAMRO acts by blocking the production of apolipoprotein B (apo B), the protein that provides the structural core for these atherogenic particles, including LDL and lipoprotein-a (Lp (a)).